Clinical study of transplacental anti-arrythmic treatment for fetal tachyarrythmias

Clinical study of transplacental anti-arrythmic treatment for fetal tachyarrythmias - Clinical study of transplacental anti-arrythmic treatment for fetal tachyarrythmias

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026378

Enrollment

Registered

2017-03-03

Start date

2017-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fetal tachyarrythmia (Supraventricular tachycardia, Atrial flutter)

Interventions

These anti-arrythmic agent are administered to pregnant women as treatment for fetal supraventricular tachycardia with short VA interval or atrial flutter. Administration is started with 2nd for fetal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 sustained fetal tachyarrythmias 2 gestational age 22w0d~36w6d 3 singleton 4 Informed consent has been obtained from patient

Exclusion criteria

Exclusion criteria: 1 it is impossible to obtain informed consent due to the mental problem 2 the treatment causes serious risk for mother's health 3 Doctor judged inappropriate for the treatment

Design outcomes

Primary

Measure	Time frame
disappearance of fetal tachyarrythmias in more than half of 30min fetal echocardiogram and/or 40min cardiotocogram	—

Secondary

Measure	Time frame
1 Intrauterine Fetal Death 2 Rate of preterm birth 3 Rate of cesarean section 4 Improvement of fetal heart rate and/or fetal hydrops 5 Neonatal arrythmias 6 CNS findings in neonate 7 Survival rate at 1 month 8 Tachyarrythmias at 1 month	—

Countries

Japan

Contacts

Public ContactMaki Inoue

Gunma University Hospital Department of Obstetrics and Gynecology

m-inoue@gunma-u.ac.jp+81-27-220-8429

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026